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Summary 
Background: Metronidazole resistance is a common problem in most Asian countries, and 
clarithromycin has been widely used in Hong Kong. We determined the prevalence of H. pylori 
strains resistant to metronidazole and clarithromycin in Hong Kong and assessed the effect on 
eradication rates. We also determined the genetic mutation in relation to phenotypic divergence 
in clarithromycin resistant strains. 
Methods: H. pylori were cultured from gastric biopsies obtained from 87 patients during upper 
endoscopy and minimal inhibitory concentrations (MIC) of metronidazole and clarithromycin 
were determined by Etest and agar dilution methods. Mutations in clarithromycin resistant strains 
were identified by PCR and restriction analysis. RAPD fingerprinting were performed on 
clarithromycin resistant and susceptible isolates. 
Results: The prevalences of H. pylori strains resistant to metronidazole and clarithromycin were 
49.4% and 10.8% respectively in Hong Kong. Dual resistance to metronidazole and 
clarithromycin were found in 7.2% of patients. The agreement between Etest and agar dilution 
methods was determined by error-rate bounded analysis as 95.4% for metronidazole and 100% 
for clarithromycin, respectively. Dual resistant strains reduced the eradication rate to 66.7%. 
Among clarithromycin resistant strains tested, all were due to A2144G point mutation in 23S 
rRNA gene. RAPD fingerprinting suggested various phenotypically mixed populations. 
Conclusions: The prevalence of metronidazole resistant H. pylori strains remained static while 
the prevalence of clarithromycin resistant strains was not rare in Hong Kong. An alarming 7.2% 
of patients were dual resistant to the antimicrobials and had a definite impact on treatment 
success. All cases of resistance to clarithromycin were due to A2144G mutation in 23S rRNA of 
H. pylori. Mixed population is another factor affecting the eradication rate. 
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INTRODUCTION 
      Helicobacter pylori infection is a major cause of chronic active gastritis and peptic ulcer 
disease and has been implicated in the development of gastric carcinoma 1-3. Eradication of H. 
pylori provides the most effective treatment for peptic ulcer disease. This generally requires use 
of a combination of antimicrobial agents, typically two antimicrobial agents and a proton pump 
inhibitor 4,5. Primary resistance to some of the most effective antimicrobials, metronidazole and 
clarithromycin, is commonplace in many societies and is of particular concern as the major 
reason for treatment failure 6-8. The prevalence of H. pylori resistance to metronidazole, for 
example, ranges from 10-45% in the United States and Europe to more than 50% in many 
developing countries.  Increasing prevalence of resistance to clarithromycin have also been 
reported 8-10 , and it has been suggested that the prevalence of resistance to metronidazole and 
clarithromycin has increased significantly in many countries in recent years 10-13 . Differences 
among studies in reported prevalence of metronidazole resistance are attributable, variously, to 
different and changing local patterns of metronidazole usage (typically against parasitic, 
anaerobic and other infections) in various societies, and thus inadvertent selection for 
metronidazole resistance, and also to methodological variations and difficulties in interpretation 
of susceptibility test results.  
      H. pylori infection and associated gastroduodenal diseases is a major problem in Hong Kong, 
and indeed throughout all of China. The prevalence of H. pylori infection in Hong Kong is 
around 60%; and the prevalence was much higher in certain areas of China, reaching around 
80%12. Here we have: (i) determined the prevalence of H. pylori infections that are resistant to 
metronidazole, clarithromycin, or both, in patients with upper gastrointestinal diseases; (ii) 
compared the accuracy of the Etest and agar dilution methods for routine susceptibility testing of 
metronidazole and clarithromycin; (iii) determined the effect of antimicrobial resistance on 
eradication rates; (iv) determined the genetic mutation of clarithromycin resistant (ClaR) strains 
in Hong Kong; and (v) identify differences in genotype in relation to clarithromycin resistance. 
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METHODS 
Patients and strains 
      Patients who satisfied the following inclusion and exclusion criteria were prospectively 
recruited into this study. Inclusion criteria included age between 18 and 80 years with symptoms 
of dyspepsia, and no previous antimicrobial therapy to eradicate H. pylori infection. Exclusion 
criteria included previous gastric surgery, any use of bismuth, antimicrobial agents, H2-receptor 
antagonists, proton pump inhibitors or sucralfate within four weeks prior to endoscopic 
examination, or any of several concomitant medical illnesses including cardiac, respiratory, renal 
and liver diseases. The study population was randomly selected from three clinical studies on 
non-ulcer dyspepsia, duodenal ulcer and gastric ulcer. The studies were approved by local 
institutional human research review committee. One biopsy from the gastric antrum was collected 
during upper endoscopy, and transported to the laboratory immediately. H. pylori was cultured 
from gastric biopsy specimens on selective media (Columbia agar with 7% horse blood and H. 
pylori selective supplement; Oxoid, Basingstoke, UK) under microaerophilic conditions 
produced by a gas-generating system (CampyGenTM; Oxoid, Basingstoke, UK) for 3 to 6 days. H. 
pylori was identified by Gram staining and by positive urease, oxidase, and catalase tests. 
Suspensions of H. pylori were stored at -800C in brain heart infusion broth (BHI; Oxoid, 
Basingstoke, UK) with 20% glycerol.  
 
Preparation for antimicrobial sensitivity testing  
 H. pylori was subcultured on Columbia agar with 7% horse blood to ensure good growth. 
Suspensions in BHI, yielding a viable count of 3x108 cfu/ml (equivalent to 1 McFarland turbidity 
standard unit), were used as the inoculum for agar dilution and Etest susceptibility tests. H. pylori 
strain 26695 with six derivatives that were resistant to different concentrations of metronidazole, 
from the Berg laboratory, were included in each run to serve as controls. 
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Agar dilution 
     Metronidazole powder (Fluka, Switzerland) and clarithromycin powder (kindly supplied by 
Abbott Laboratories, Chicago, USA) were dissolved in distilled water and ethanol separately, and 
were subsequently diluted in distilled water according to NCCLS document M11-A2 14. 
Columbia blood agar plates containing metronidazole in concentrations ranging from 0.5 to 128 
μg/ml or clarithromycin in concentrations ranging from 0.125 to 32 μg/ml were prepared. One 
microlitre of each isolate suspension was inoculated onto antimicrobial containing plates, to give 
a bacterial density of 3x105 CFU/spot. Plates with no antimicrobials were inoculated at the 
beginning and end of each run as growth controls. Plates were allowed to dry, and then incubated 
for 72 hrs at 370C under microaerophilic conditions.  
 
Etest  
      From each suspension, 100 μl were spread on surfaces of Columbia blood agar plates with a 
cotton swab. A single metronidazole or clarithromycin Etest strip (AB Biodisk, Sweden) was 
applied to the surface of each dried plate. After incubation in microaerophilic conditions at 370C 
for 72 hours, results were read according to the manufacturer’s guidelines. 
 
Definitions of susceptibility 
      After 72 hours incubation under microaerophilic conditions, the MICs were determined. The 
MIC was recorded as the lowest concentration that inhibited visible growth of organisms. For 
metronidazole, resistance was defined as an MIC of >8 mg/ml. For clarithromycin, resistance was 
defined as an MIC of >2 mg/ml.  
 
Detection of mutations to clarithromycin resistance in 23S rRNA genes 
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Strains isolation and DNA preparation 
      Strains initially identified as clarithromycin resistant (ClaR) were grown on plates without 
clarithromycin for three days and subcultured on clarithromycin-containing plates (0.5 μg/ml) to 
obtain ClaR isolates. Five single colonies were picked from the drug-free plate and susceptibility 
testings of clarithromycin were done. Genomic DNA was prepared from confluent plate cultures 
of ClaR and ClaS isolates by the CTAB-phenol extraction  method 15. 
 
PCR amplification:  
      A 613 bp segment containing the peptidyltransferase region of the 23S rRNA gene, which 
contains the known sites of mutation to clarithromycin resistance, was amplified with the primers 
"forward" (5’-GGCTCTTTGAGTCCTTTTAGGACAA-3’) and "reverse" (5’- 
CTCCATAAGAGCCAAAGCCCTTACT-3’). PCR was performed using 10 ng of genomic DNA, 
10 pmoles of primer, 1 unit of Taq DNA polymerase, 2.5 mM each of dATP, dTTP, dCTP, dGTP 
with standard PCR buffer in a volume of 20 µl for 35 cycles, with the following cycling 
conditions: 94°C for 1 min ; 65°C for 1 min and 72°C for 1 min. PCR amplified product was then 
purified by Qiagen PCR purification kit (Chatsworth, CA). 
 
Restriction digestion of PCR products 
      The two most common mutations to clarithromycin resistance (changes 2143 A to G and 
2144 A to G) result in new sites for restriction endonucleases BbsI and BsaI, respectively 15.  To 
test for these changes in ClaR mutants, eight microliters of purified PCR product were incubated 
with BsaI for 24 hours at 500C, and separately with BbsI for 24 hours at 370C. Products were then 
electrophoresed in 1% agarose gels.  
 
RAPD fingerprinting 
      Random amplified polymorphic DNA (RAPD) PCR17 was carried out in 25 µl containing 10 
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mM Tris-HCl (pH 8.3), 50 mM KCl, 4 mM MgCl2, 0.001% gelatin, 20 ng of H. pylori  genomic 
DNA, 20 pmoles of primer 1254 (5'-CCGCAGCCAA), 1 unit Amplitaq DNA polymerase and 
250 mM each of dCTP  dATP, dGTP, dTTP for 45 cycles of : 94°C, 1 min; 36°C, 1 min; and 
72°C, 2 min, in a Perkin-Elmer TC480 thermal cycler. After PCR, 8 µl aliquots of products were 
electrophoresed in 1% agarose gels containing 0.5 mg/ml ethidium bromide and photographed 
under UV light. 
 
Data Analysis 
      The error rate bounded method of Metzler and DeHaan 18 was used to compare MIC of agar 
dilution with MIC of Etest. The chi-square test and Fisher’s exact test were used to compare the 
difference in prevalence of drug-resistant H. pylori strains between different gender, age group, 
and endoscopic diagnosis of patients, and differences in eradication rates. A P value of <0.05 was 
considered significant. 
 
RESULTS 
Prevalence of Metronidazole and Clarithromycin Resistance 
      Eighty-seven patients (42 males, mean age 47.5 years; 45 females, mean age 51.6 years) who 
satisfied the inclusion and exclusion criteria were included in this study. H. pylori isolates were 
obtained from antral biopsy specimens of each of them. Endoscopic evaluation of the patients 
revealed 50 subjects with gastritis, 29 with duodenal ulcer, 7 with gastric ulcer, and 1 with gastric 
and duodenal ulcers. Of the 87 H. pylori isolates, 83 gave the same results by agar dilution and 
Etest methods. Resistance to metronidazole was found in 49.4% (41/83) isolates and resistance to 
clarithromycin in 10.8% (9/83). Six of the nine (7.2%) strains resistant to clarithromycin were 
also resistant to metronidazole (Table 1). Among these six patients infected with strains resistant 
to both metronidazole and clarithromycin, three were males and three were females. Endoscopic 
exam showed that three patients suffered from duodenal ulcer and three from chronic gastritis. 
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      No significant differences in resistance rates to metronidazole and clarithromycin were seen 
between men and women (p>0.05). However, prevalence of metronidazole resistance was higher 
in strains from 18-40 year old patients (70.8%, 17/24) than from 41-60 or 61-80 year old patients 
(44.7%, 17/38; and 33.3%, 7/21, respectively) (p<0.05). Resistance to metronidazole was slightly 
higher in patients with duodenal ulcer than with chronic gastritis, but this difference was not 
significant (p>0.05). No differences were found in the prevalences of clarithromycin resistance 
among patients of different age groups or among patients with different diseases (p>0.05; Table 
2).  
 
Comparison of Etest and agar dilution results for metronidazole and clarithromycin 
      For many organisms, tests for colony formation by bacterial suspensions on agar containing 
defined levels of an antimicrobial (agar dilution) can be used as “gold standard” against which 
other methods of drug susceptibility testing can be judged. When resistance and susceptibility of 
H. pylori to metronidazole determined by agar dilution and Etest were compared, there was 
95.4% (83/87) category agreement using the breakpoint of <=8 μg/ml as susceptible (Figure 1). 
Etest gave 2.3% (2/87) major error (resistant by the Etest and susceptible by the agar dilution 
method) and 2.3% (2/87) very major error (susceptible by the Etest and resistant by the agar 
dilution method).  
      The clarithromycin Etest, in contrast, correlated perfectly with the clarithromycin agar 
dilution, when using the breakpoint of <=2 ug/ml as susceptible (Figure 2); 100% (87/87) 
agreement, with no major error and very major error.  
 
Mutation in 23S rRNA gene in clarithromycin resistant strains 
      Only five strains (strains 1, 2, 3, 4, 5) that were initially classified as clarithromycin 
resistance were able to grow on medium with clarithromycin (0.5 μg/ml), the other four strains 
(strains 6, 7, 8, 9) were likely to have mixed resistant and sensitive strains, with the resistant 
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colonies not surviving. Strain 4 was about 50% ClaR, whereas for strains 2 and 5, only about 5% 
isolates showed ClaR. All these five ClaR strains had the new BsaI site which is characteristic of 
the A2144G point mutation in 23S rRNA gene (Figure 3). None had a new BbsI cleavage site 
which is characteristic of the other relatively common mutation (A2143G). 
      For the mixed infection, defined as identification of both ClaR and ClaS single colonies from 
a single patient, (strains 2, 4, 5), ClaR and ClaS colonies were isolated and RAPD fingerprinting 
were performed. Different RAPD patterns were found between ClaR and ClaS colonies for strain 
4, whereas the identical RAPD patterns were observed between ClaR and ClaS colonies for 
strains 2 and 5 (Figure 4).  
 
Eradication rate and resistance 
      Eighty of the 83 patients included in this study received triple therapy containing both 
metronidazole and clarithromycin, together with either omeprazole or ranitidine bismuth citrate. 
At 4 wks after the completion of treatment, 6 patients defaulted follow-up endoscopy and hence 
evaluation of compliance and treatment success was not possible. 74 patients fulfilled the follow-
up endoscopy with biopsies and C13 breath test. Successful eradication was confirmed by 
negative results in all three diagnostic tests: rapid urease test, histology, and C13 urea breath test. 
Table 3 illustrated the effect of metronidazole and clarithromycin resistance on treatment efficacy. 
There was a higher eradication rate in those with dual susceptible strains (33/35, 94.3%) than 
those with dual resistant strains (4/6, 66.7%) (p=0.095). Resistance to metronidazole or 
clarithromycin alone did not significantly affect the eradication rates (90.3% and 100% 
respectively) compared with dual susceptible strains (94.3%).  
 Strains 2 and 5 were both dual resistant strains. The resistant strains contributed about 5% of the strain 
population (see above). Eradication was successful for strain 2 but not strain 5. Strain 4 was sensitive to 
metronidazole and the ClaR strains contributed about 50% of the strain population. Eradication was successful for 
strain 4. 
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DISCUSSION 
      The increasing prevalence of strains resistant to some of the most commonly used 
antimicrobial agents is an important cause for failures to eradicate H. pylori infections.  Therefore, 
routine antimicrobial susceptibility testing of H. pylori by simple, inexpensive and standardized 
methods is recommended especially for patients who repeatedly fail treatment. In this study, the 
susceptibility of 87 H. pylori isolates to metronidazole and clarithromycin in vitro was 
determined by agar dilution and Etest methods, with generally excellent agreement (95% for 
metronidazole; 100% for clarithromycin). Therefore Etest is suitable for testing H. pylori 
resistance to antimicrobials, being simple to perform, less affected by bacterial inoculum size 
than agar dilution19 and ready to test single isolates as needed. 
     The present study showed that primary resistance of H. pylori to metronidazole and 
clarithromycin were found in 49.4% and 10.8% of patients respectively in Hong Kong. This 
primary resistance rate for metronidazole was similar to that observed over the past three years in 
this area 20, and further supported that the prevalence of metronidazole resistant H. pylori strains 
in Hong Kong was somewhere between that of the developed and the developing countries9, 21, 22. 
Increased prevalence of resistance to metronidazole in patients in Hong Kong from 22% to 73.2% 
had been noted by a group from another center in Hong Kong from 1991 to 1996 23, whereas we 
did not observe such trend over the past three years (1996-1998). Traditionally metronidazole has 
been prescribed in Hong Kong, as in many other societies, for the treatment of gynecological 
infection. It is also widely used for treatment of anaerobic infections and amoebiasis in men and 
women, and no significant differences in the rate of metronidazole resistance were found between 
men and women in our study.  
      The prevalence of resistance to clarithromycin is generally much lower than that to 
metronidazole, although still very significant from a public health perspective: for example, less 
than or equal to 15% in Europe 9, 9.1% in Japan 8, and 6.1-12.6% in the United States 10, 24 . The 
resistance to clarithromycin observed in our study was 10.8% and was consistent with the data 
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reported worldwide. Although the overall prevalence of primary resistance to clarithromycin was 
still low, the increase in secondary resistance over a short period of time was worrisome. The 
emergence of ClaR strains after ineffective treatment against H. pylori is easily observed 10 and 
we also found that more than 90% isolates cultured after clarithromycin-based treatment were 
resistant to the drug (data not shown). However, most of the resistance found in patients may 
reflect a history of usage of macrolides by them or their close contacts for other illnesses, 
generally at doses sufficient to select for new ClaR mutants (i.e. at doses that impair growth of 
normal wild type H. pylori, but that do not fully eradicate infection). Especially in areas of high 
prevalence of primary metronidazole resistance, metronidazole resistance could reduce efficacy 
of triple therapy and leads to secondary clarithromycin resistance, and these dual resistant strains 
are difficult to eradicate7. 
       Most or all clarithromycin resistance is though to involve base substitution mutations in 23S 
rRNA at sites critical for macrolide interaction 25. We also confirmed that all the strains identified 
as ClaR were due to A2144G point mutation in 23S rRNA gene in our study. However, a study 
reported that clarithromycin resistance was not stable in 45% of normally ClaR strains of H. 
pylori in vitro and this phenomenon was also observed in vivo 15, 26. In the present study, we 
found that for the nine strains that were initially confirmed as ClaR, three strains were mixed 
populations with ClaR and ClaS colonies and four strains lost the resistant population after 
storage and transportation. The possible reason might be that these four strains were also mixed 
populations, with a large quantity of ClaS colonies and a small quantity of ClaR colonies. The 
ClaS colonies showed a competitive growth advantage over the ClaR colonies, and the ClaR 
colonies did not survive after initial storage. Using a multiplex sequence analysis, Wang et al 
confirmed the decreased vigor of growth resulting from some other types of mutations (not A to 
G mutation) to clarithromycin resistance 27. Furthermore, the instability of clarithromycin 
resistance might also be attributed to the two copies of 23S rRNA per H. pylori genome. 
Mutation in one copy seems sufficient to confer clarithromycin resistance in certain strains 28. 
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      For the three strains confirmed as mixed populations, RAPD fingerprinting of isolates from 
ClaR and ClaS colonies were compared. Different RAPD fingerprints were found in one patient 
(strain 4), meaning that the patient was infected with two different strains, one ClaR and one 
ClaS. An identical RAPD fingerprint was found for the other two patients (strains 2 and 5), 
suggesting that these patients were infected with a single strain, with part of the colonies 
acquiring resistance to clarithromycin via point mutation in 23S rRNA gene. Successful treatment 
was found in strains 2 and 4 but not strain 5. Several important points related to clarithromycin 
resistance were illustrated here. Mixed infections in relation to clarithromycin susceptibility were 
common in Hong Kong, as opposed to the study by Dore et al who showed that all isolates 
(multiple and single colonies) from ClaR patients were purely resistant 29. Strain 4 showed 50% 
ClaR and 50% ClaS population with a different RAPD pattern, suggesting that a mixed infection 
of at least two strains co-existed in the stomach. Strains 2 and 5 had the same RAPD pattern, with 
the ClaR population contributed only 5% of the population. One of the strains was eradicated 
while one was not. This supported the hypothesis that acquired resistance may actually represent 
emergence of resistant organisms that were already present in the stomach rather than actual 
development of resistance 30.  Recently, another study reported that treatment failure could be due 
to either a single strain that had acquired resistance to clarithromycin, or due to presence of 
different strain types of H. pylori 31. Hence from our finding and others, the outcome of treatment 
did not depend only on the acquired clarithromycin resistance. Pre-treatment work up for 
clarithromycin susceptibility may be necessary to understand better the clinical correlation with 
in vitro susceptibility. More studies need to be done in regard to clarithromycin, and in 
conjunction with metronidazole susceptibility.  
      Dual resistance to metronidazole and clarithromycin might become a major problem in H. 
pylori eradication. Although in the present study and in some other studies 32,33, high eradication 
rates were achieved by treatment regimens containing both metronidazole and clarithromycin 
even for metronidazole resistant strains, the rate decreased dramatically for ClaR strains. In our 
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study, six of 87 patients (7.2%) had dual resistant infections, despite their absence of prior 
treatment for H. pylori infection. This dual resistance would certainly affect the success of 
treatment, with only 66.7% of patients being eradicated. In countries where metronidazole 
resistance is common, it may be advisable not to use the combination of metronidazole and 
clarithromycin as the first line treatment, to avoid the emergence of more dual resistant strains.  
      Furazolidone has shown promising results in first line treatment, with the absence of 
furazolidone resistance so far. However, the drug should not be used in areas endemic for G-6-
PD deficiency, like Hong Kong and South China, for the high prevalence of G-6-PD deficiency 
was reported in 4.4% of males and 0.35% of females 34, to avoid the potential risk of 
intravascular hemolysis. Nitosoxanide may be promising as a replacement for metronidazole, 
since metronidazole resistant strains were generally sensitive to nitosoxanide. This drug is still 
under clinical trials. In the near future, the follow ups to the H. pylori genome projects may result 
in new potential drugs and vaccines targeted to essential functions that have not been used to date, 
and should thereby allow effective anti-H. pylori therapies even in problem areas such as South 
China. 
      In conclusion, our data indicated that around half of H. pylori infections in Hong Kong were 
metronidazole resistant, and that clarithromycin resistance was also disturbingly common. The 
high prevalence of dual resistance needs special attention and new therapeutic approaches. 
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Figure Legends 
Figure 1. Error-rate bounded analysis of metronidazole Etest MIC versus agar dilution MIC for 
87 H. pylori strains. 
Figure 2. Error-rate bounded analysis of clarithromycin Etest MIC versus agar dilution MIC for 
87 H. pylori strains. 
Figure 3. Detection of the point mutation at 2144 (A to G) in 23S rRNA gene by BsaI digestion 
of PCR products. Lane M: 100 bp DNA ladder (Gibco BRL, Gaithersburg, MD, USA). Lane P: 
point mutation positive control; Lane N: point mutation negative control. Lane 1-5: strains still 
resistant to clarithromycin after preservation and transportation. Strains 1-3 each had A2144G 
point mutation. Strain 4 was a mixed infection with some colonies having A2144G point 
mutation and some colonies don’t. Only 5% of colonies from strain 5 were confirmed as resistant 
to clarithromycin. DNA was prepared from the ClaR colonies and the A2144G mutation was 
detected by digesting with BsaI repeatedly (data not included in this figure). Lane 6-8: strains 
sensitive to clarithromycin after preservation and transportation, no A2144G point mutation was 
found. 
Figure 4. RAPD fingerprinting of ClaS and ClaR colonies from strains 2, 4, and 5.  M: 1kb DNA 
ladder (Gibco BRL, Gaithersburg, MD, USA); S: isolates from ClaS colonies; R: isolates from 
ClaR colonies. Strains (2, 4, 5) corresponding to that of figure 3. Different RAPD patterns were 
found for strain 4, meaning that this patient had a mixed infection of two different strains with 
one ClaS and one ClaR. Identical RAPD patterns were found for ClaS and ClaR isolates from 
strains 2 and 5. 
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Table 1. Results of susceptibility test of 83 H. pylori isolates to metronidazole and 
clarithromycin 
 
    No. of Patients    Metronidazole     Clarithromycin      Resistance 
Rate (%) 
 
          39      S   S     47.0 
              6       R   R       7.2 
              3      S   R       3.6 
          35      R   S     42.2 
 
Total 83        100.0 
      
 S=susceptible, R=resistant 
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Table 2. Prevalence of metronidazole and clarithromycin resistance of 83 H. pylori isolates 
according to their clinical information 
  
Clinical         metronidazole   clarithromycin       
Information         resistance (%)     p value resistance (%)  p value 
 
Gender 
      Male (n=40)  20 (50)     3 (7.5)       
     Female (n=43)      21 (49)             1.0  6 (14)            0.49 
 
Age (years) 
      18-40 (n=24)  17 (71)   5 (21)   
      41-60 (n=38)  17 (45)   1 (2.6) 
      61-78 (n=21)   7 (33)     0.01  3 (14)     0.42 
 
Endoscopic Diagnosis 
  Gastritis (n=49)  23 (47)    5 (10)  
  Duodenal ulcer (n=27) 17 (63)     3 (11)  
  Gastric ulcer (n=6)   1 (17)    1 (17)  
  Complex ulcer (n=1)   0 (0)      0.57  0 (0)     0.82 
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Table 3. H. pylori eradication rate and metronidazole / clarithromycin resistance 
 
Eradication rates Mtz susceptible  Mtz resistant           Total 
 
Cla susceptible  33/35 (94.3%)   28/31 (90.3%)  61/66 (92.4%) 
Cla resistant    1/1   (100%)      4/6   (66.7%)    5/7   (71.4%) 
Total   34/36 (94.4%)   32/37 (86.5%)  66/73 (90.4%) 
 
Mtz : metronidazole 
Cla : clarithromycin 
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agar 
dilution 
MIC 
(ug/ml) 
          
>128                                                                                                     15 
 
128                                                                                                         7 
 
64                                                                                                           6 
 
32                                                              1      1    1            1               3 
 
16                               1      1                             1         3                        2 
           
 8                                                          1 
 
 4                                1      4           1   1           1 
                                
 2              2      1        5  3  6       2       1       1   
 
 1              3   3           2  2 
 
<0.5          4 
                                                                
           <0.25    0.5      1      2       4       8      16      32      64     128     >256  Etest MIC (ug/ml) 
 
Figure 1 
 
                            
 
 
 
                 Wang- Page 24 
 
 
agar 
dilution 
MIC 
(ug/ml) 
 
   >32                                                                                                                            5 
 
     32                                                                                                                            2 
 
    16                                                                                                   1          1 
 
      8                                                                                               1 
 
      4 
             
      2 
 
      1                  1 
 
   o.5                                    1                    1             1 
 
   0.25                                  1     1      1     4    1    5 
 
<0.125        16  10  12   4    9   4   5 
                                                                                                              
                  <0.016   0.032  0.064  0.125   0.25     0.5      1        2       4       8      16     >32 
                                                                                                                         Etest MIC (ug/ml) 
 
Figure 2 
 
 
